| WNT/β-catenin pathway activation correlates with immune exclusion across human cancers JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski Clinical Cancer Research 25 (10), 3074-3083, 2019 | 572 | 2019 |
| T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection JA Trujillo, RF Sweis, R Bao, JJ Luke Cancer immunology research 6 (9), 990-1000, 2018 | 378 | 2018 |
| Molecular drivers of the non–T-cell-inflamed tumor microenvironment in urothelial bladder cancer RF Sweis, S Spranger, R Bao, GP Paner, WM Stadler, G Steinberg, ... Cancer immunology research 4 (7), 563-568, 2016 | 342 | 2016 |
| Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas F Meric-Bernstam, RF Sweis, FS Hodi, WA Messersmith, RHI Andtbacka, ... Clinical cancer research 28 (4), 677-688, 2022 | 192 | 2022 |
| Silver-catalyzed [2+ 2] cycloadditions of siloxy alkynes RF Sweis, MP Schramm, SA Kozmin Journal of the American Chemical Society 126 (24), 7442-7443, 2004 | 161 | 2004 |
| Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, ... The lancet oncology 22 (7), 946-958, 2021 | 149 | 2021 |
| Germline genetic contribution to the immune landscape of cancer RW Sayaman, M Saad, V Thorsson, D Hu, W Hendrickx, J Roelands, ... Immunity 54 (2), 367-386. e8, 2021 | 131 | 2021 |
| Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study F Meric-Bernstam, RF Sweis, S Kasper, O Hamid, S Bhatia, R Dummer, ... Clinical Cancer Research 29 (1), 110-121, 2023 | 92 | 2023 |
| Brønsted acid-promoted cyclizations of 1-siloxy-1, 5-diynes J Sun, SA Kozmin Journal of the American Chemical Society 127 (39), 13512-13513, 2005 | 92 | 2005 |
| Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop D Bedognetti, M Ceccarelli, L Galluzzi, R Lu, K Palucka, J Samayoa, ... Journal for immunotherapy of cancer 7, 1-23, 2019 | 83 | 2019 |
| Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy C Labbate, K Hatogai, R Werntz, WM Stadler, GD Steinberg, S Eggener, ... Journal for immunotherapy of cancer 7, 1-6, 2019 | 83 | 2019 |
| Wnt–β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression J Quandt, S Arnovitz, L Haghi, J Woehlk, A Mohsin, M Okoreeh, ... Nature immunology 22 (4), 471-484, 2021 | 68 | 2021 |
| Do clinicians know which of their patients have central venous catheters? A multicenter observational study V Chopra, S Govindan, L Kuhn, D Ratz, RF Sweis, N Melin, R Thompson, ... Annals of internal medicine 161 (8), 562-567, 2014 | 66 | 2014 |
| FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer A Kacew, RF Sweis Frontiers in Immunology 11, 575258, 2020 | 64 | 2020 |
| Hallmarks of resistance to immune-checkpoint inhibitors M Karasarides, AP Cogdill, PB Robbins, M Bowden, EM Burton, ... Cancer Immunology Research 10 (4), 372-383, 2022 | 58 | 2022 |
| Tumor endothelial inflammation predicts clinical outcome in diverse human cancers SP Pitroda, T Zhou, RF Sweis, M Filippo, E Labay, MA Beckett, ... Public Library of Science 7 (10), e46104, 2012 | 52 | 2012 |
| The development of STING agonists and emerging results as a cancer immunotherapy JB Hines, AJ Kacew, RF Sweis Current oncology reports 25 (3), 189-199, 2023 | 44 | 2023 |
| Mechanistic and pharmacologic insights on immune checkpoint inhibitors RF Sweis, JJ Luke Pharmacological research 120, 1-9, 2017 | 43 | 2017 |
| Analysis of impact of post-treatment biopsies in phase I clinical trials RF Sweis, MW Drazer, MJ Ratain Journal of Clinical Oncology 34 (4), 369-374, 2016 | 41 | 2016 |
| Praluzatamab ravtansine, a CD166-targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial V Boni, MJ Fidler, HT Arkenau, A Spira, F Meric-Bernstam, N Uboha, ... Clinical Cancer Research 28 (10), 2020-2029, 2022 | 35 | 2022 |